Dr. Kevin Saunders, a leader at the Duke Human Vaccine Institute, highlights the advancements in vaccine research, emphasizing the use of computational design, AI, and mRNA technology. Duke is at the forefront with significant progress in HIV, coronavirus, and cancer vaccines, and is developing pan-coronavirus and pan-influenza vaccines.

Dr. Aditee Narayan, a leader in medical education at Duke, spearheaded the Patient First curriculum, emphasizing modern, patient-centered care and interdisciplinary collaboration. She envisions future physicians as change agents, equipped with clinical skills and the ability to innovate and address health care disparities.

Nicole Calakos, MD, PhD, is the Lincoln Financial Group Distinguished Professor of Neurobiology and specializes in synaptic physiology research and Parkinson’s disease and other movement disorders. She highlights the transformative impact of big data, AI, and cell modeling on neuroscience research, emphasizing the potential for advances in regenerative therapies and neural prostheses.

In a new study, scientists at Duke University School of Medicine have identified a potential new front in the battle against fungal infections, a growing health threat. By determining two structures of a crucial enzyme involved in fungal survival, scientists have pinpointed a pathway that could be key to developing new antifungal drugs.

Health experts at Duke University School of Medicine are scrutinizing the myriad ways in which shifting environmental conditions, from sweltering temperatures to severe storms, shape our well-being.  In university laboratories, North Carolina homes and on the coastlines of faraway places, they've learned not everyone is equally at risk. Their efforts involve pinpointing solutions to help those susceptible to environmental disruptions, which could affect respiratory and cardiovascular health, food security, infection resilience, and mental health.

Nancy Andrews, MD, PhD, is Executive Vice President and Chief Scientific Officer at Boston Children's Hospital and Professor in Residence in Pediatrics at Harvard Medical School. She was Dean of the School of Medicine and Vice Chancellor for Academic Affairs at Duke University from 2007-2017.

R. Sanders “Sandy” Williams, MD’74, HS’77-’80, is a professor of medicine in the Division of Cardiology at Duke University School of Medicine. He was Dean of the School of Medicine from 2001-2007 and Senior Vice Chancellor of Academic Affairs from 2001-2010. He currently serves in advisory roles on issues including Duke Science and Technology and research translation and commercialization.

Mary E. Klotman, BS’76, MD’80, HS’80-85, is Executive Vice President for Health Affairs at Duke University, Dean of Duke University School of Medicine, and Chief Academic Officer for Duke University Health System. She was appointed dean in 2017, after serving for seven years as chair of the Department of Medicine, and re-appointed in 2022.

Three individuals within the School of Medicine and one Duke Health team were among the recipients of the prestigious 2024-25 Duke Presidential Awards.   

Last year, Duke became the first institution in North Carolina to offer lecanemab, the first drug targeting the underlying processes of Alzheimer’s disease that has shown a clinical benefit. Duke now conducts the largest lecanemab clinic in the state, giving early-stage Alzheimer’s patients the gift of time and raising awareness about the need for more research.